StreetAlpha.app
Home › Stocks › MNKD

Mannkind Corp (MNKD)

Healthcare
$4.07
▲ +2.91%
LAST CLOSE · NOV 17

MannKind develops and sells inhaled and wearable treatments for diabetes, heart failure and lung conditions. It last closed at $4.07 on Nov 17, up 2.91% on the day. The average 12-month price target from 4 analysts is $7.50 (+84.3% from the last close), with a high of $10.00 and a low of $5.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (3 buy, 1 hold, 0 sell).

AI Auto Pilots
Is MNKD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$413.4M
+31.7% vs a year ago
Net income
−$74.8M
−356.0% vs a year ago
EPS (diluted)
−$0.24
−340.0% vs a year ago
Free cash flow
−$78.4M
−19.0% margin
Valuation
Market cap
$1.3B
321.6M shares
P/E
–
No P/E while losing money
Price to sales
3.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.3M
At Sep 30
Debt
$319.4M
At Sep 30
Shareholder equity
−$37.3M
Shares outstanding
321.6M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $75.4M$75.4MFY2021FY2022: $99.8M$99.8MFY2022FY2023: $199.0M$199.0MFY2023FY2024: $285.5M$285.5MFY2024FY2025: $349.0M$349.0MFY2025

From MNKD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
3 Buy1 Hold0 Sell
Each firm's latest rating on MNKD in the past 90 days
Average 12-month target
$7.50
▲ 84.3% upside

Based on 4 analysts who set a price target on MNKD in the past 90 days. The average target is $7.50, with a high of $10.00 and a low of $5.00, compared with the last close of $4.07.

$3$5$8$11PAST 21 TRADING DAYS12-MONTH TARGETSHIGH $10AVG $7.50LOW $5May 26LAST CLOSE+12 MO$3$5$8$11PAST 21 DAYSTARGETSHIGH $10AVG $7.50LOW $5May 26LAST CLOSE+12 MO
Highest target$10.00
Average target$7.50
Lowest target$5.00
Latest rating changes
RBC CapitalTarget raised
Nov 6Hold$3.50 → $5
Cantor FitzgeraldTarget raised
Nov 6Buy$6.50 → $10
Chardan CapitalInitiated
Oct 19Buy$10
Truist SecuritiesMaintained
Oct 7Buy$5
Cantor FitzgeraldReiterated
Sep 11Buy$6.50
DateFirmActionRatingPrice target
Nov 6RBC CapitalTarget raisedHold$3.50 → $5
Nov 6Cantor FitzgeraldTarget raisedBuy$6.50 → $10
Oct 19Chardan CapitalInitiatedBuy$10
Oct 7Truist SecuritiesMaintainedBuy$5
Sep 11Cantor FitzgeraldReiteratedBuy$6.50
Loading…

Technical Analysis

MNKD · as of the Nov 17 close · updated after every close
Turning up

The stock is 9% above its 20 day and 12% above its 50 day average. It is 11% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62). The nearest support is the Pivot at $4.05, and the nearest resistance the swing high (Jul 31) at $4.14.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchNormal
VolatilityNormal, 5.0%/day
Key levels
$6.5152 week high+60.0%
$4.20Pivot R1+3.2%
$4.14Swing high (Jul 31)+1.7%
$4.07Last close
$4.05Pivot−0.5%
$3.92Pivot S1−3.7%
$3.90Swing low (Aug 31)−4.2%
$3.80100 day average−6.6%
$3.7120 day average−8.8%
$3.63200 day average−10.8%
$3.5750 day average−12.3%
$2.2352 week low−45.2%
Indicators
RSI (14)61.73Strong, overbought above 70Neutral
MACD0.19Above its signal lineBullish
Stochastic76.3Middle of its rangeNeutral
ADX (14)26.9Trending up
Williams %R-25.8Oversold below −80, overbought above −20Neutral
CCI (20)67.2Oversold below −100, overbought above 100Neutral
Rate of change+9.1%Change over 10 sessionsBullish
ATR (14)$0.20Typical daily range, 5.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for MNKD

What happened before

See how MNKD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MNKD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MNKD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MNKD in the last 90 days.

Loading…

See today’s whale options flow across the market →

MNKD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼98 buying vs 124 selling
  • ▲Held by funds +3.1 pts
  • ▼Funds holding -11
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding250261−4.2%
In funds' top 10220.0%
Held by funds59.9%56.8%+3.1 pts
New / increased30 / 6849 / 95−31.9%
Reduced / sold out85 / 3962 / 40+21.6%
Put/call ratio0.005.66−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MNKD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNKD is in one of them and how their past MNKD trades turned out.

MNKD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MNKD in an article yet. Here's the latest on the wider market.

About Mannkind

MannKind is a biopharmaceutical company based in Danbury, Connecticut. Its products include Afrezza, an inhaled mealtime insulin for adults with diabetes, V-Go, a wearable insulin delivery device, and Furoscix, a home-use treatment for fluid buildup linked to heart failure and chronic kidney disease. Its Tyvaso DPI treatment for pulmonary hypertension is sold by partner United Therapeutics, which pays MannKind royalties. The company makes its inhalable powders and inhalers at its Connecticut facility and sells Afrezza in the United States and through partners in other countries.

Headquarters
Danbury, CT
Founded
1991